Sponsor:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Code:
NCT07287137
Conditions
COVID -19
COVID - 19
COVID 19
Influenza
Respiratory Virus
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine
Novavax recombinant protein vaccine
Brief summary:
Conditions
COVID -19
COVID - 19
COVID 19
Influenza
Respiratory Virus
Study ID
NCT07287137
Start date
Nov 12, 2025
Status verified date
Oct, 2026
Completion date
Sep, 2027
Anticipated
Primary completion date
Sep, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Enrollment
54 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Prevention
Arms
active comparator: For fall of 2026, Arm 1 of the study will be the Pfizer-BioNTech mRNA COVID-19 vac
active comparator: For fall of 2026, Arm 2 of the study will be the Novavax recombinant protein vaccine
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine
Novavax recombinant protein vaccine
Primary outcome measure
Central contacts
Locations
Walter Reed National Military Medical Center
Recruiting
Bethesda, Maryland, United States, 20814
Contacts
Principal Investigator:
Anuradha Ganesan, MD
Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Last update posted
Oct 28, 2026
Last verified
Oct, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-29. This information was provided to ClinicalTrials.gov by Henry M. Jackson Foundation for the Advancement of Military Medicine on 2026-10-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.